Back to Search
Start Over
Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma
- Source :
- Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩, Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩, Clinical Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩
- Publication Year :
- 2014
- Publisher :
- HAL CCSD, 2014.
-
Abstract
- Purpose: Solitary plasmacytoma (SP) is a localized proliferation of monoclonal plasma cells in either bone or soft tissue, without evidence of multiple myeloma (MM), and whose prognosis is marked by a high risk of transformation to MM. Experimental Design: We studied the impact of FDG-PET/CT (2[18F]fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography) on the risk of transformation of SP to overt MM among other markers in a series of 43 patients diagnosed with SP. Results: Median age was 57.5 years; 48% of patients had an abnormal involved serum-free light chain (sFLC) value, and 64% had an abnormal sFLC ratio at diagnosis. Thirty-three percent had two or more hypermetabolic lesions on initial PET/CT, and 20% had two or more focal lesions on initial MRI. With a median follow-up of 50 months, 14 patients transformed to MM with a median time (TTMM) of 71 months. The risk factors that significantly shortened TTMM at diagnosis were two or more hypermetabolic lesions on PET/CT, abnormal sFLC ratio and involved sFLC, and to a lesser extent at completion of treatment, absence of normalized involved sFLC and PET/CT or MRI. In a multivariate analysis, abnormal initial involved sFLC [OR = 10; 95% confidence interval (CI), 1–87; P = 0.008] and PET/CT (OR = 5; 95% CI, 0–9; P = 0.032) independently shortened TTMM. Conclusions: An abnormal involved sFLC value and the presence of at least two hypermetabolic lesions on PET/CT at diagnosis of SP were the two predictors of early evolution to myeloma in our series. This data analysis will need confirmation in a larger study, and the study of these two risk factors may lead to a different management of patients with SP in the future. Clin Cancer Res; 20(12); 3254–60. ©2014 AACR.
- Subjects :
- Male
Cancer Research
Bone Neoplasms
Immunoglobulin light chain
Fluorodeoxyglucose F18
medicine
Biomarkers, Tumor
Humans
Positron emission
Multiple myeloma
Aged
Neoplasm Staging
Retrospective Studies
[SDV.GEN]Life Sciences [q-bio]/Genetics
business.industry
Cancer
Soft tissue
Middle Aged
medicine.disease
Prognosis
Confidence interval
3. Good health
Survival Rate
Cell Transformation, Neoplastic
Oncology
Positron-Emission Tomography
Monoclonal
Female
Immunoglobulin Light Chains
Tomography
Radiopharmaceuticals
Nuclear medicine
business
Multiple Myeloma
Tomography, X-Ray Computed
Follow-Up Studies
Plasmacytoma
Subjects
Details
- Language :
- English
- ISSN :
- 10780432 and 15573265
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩, Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩, Clinical Cancer Research, 2014, 20 (12), pp.3254--3260. ⟨10.1158/1078-0432.CCR-13-2910⟩
- Accession number :
- edsair.doi.dedup.....99315fcb9b18e972785a5ffff511ae8a
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-13-2910⟩